Latest Breaking News On - குணப்படுத்த ஜெநெடிக்ஸ் - Page 1 : comparemela.com

Share this article Share this article SUZHOU, China, Jan. 18, 2021 /PRNewswire/ Cure Genetics announced a collaboration with Boehringer Ingelheim to develop novel Adeno-Associated Virus (AAV) vectorsleveraging Cure Genetics proprietary VELP TM platform to develop next-generation gene therapies. This new collaboration combines Boehringer Ingelheim s experience in disease biology and gene therapy development with Cure Genetics AAV expertise in library construction and highly efficient in vivo AAV screening. The aim is to provide potential new AAV serotypes for patients. The clinical applications of existing AAV serotypes are limited by some of their features, such as low transduction efficiency, low tissue specificity and immunogenicity. Therefore, finding new AAV serotypes to overcome these challenges becomes critical for the majority, if not all, AAV-based gene therapies.

Qiushi liVenture fundResearch beyond bordersBoehringer ingelheimBusiness developmentAdeno associated virusCure geneticResearch beyondCure genetic chief operatingCure geneticsBoehringer ingelheim china external innovationBoehringer ingelheim cure geneticsதுணிகர நிதிஆராய்ச்சி அப்பால் எல்லைகள்போஹெரிங்கர் இஂகல்‌ஹைம்வணிக வளர்ச்சி